Skip to main content
SpringerLink
Log in

Gastrointestinal Stromal Tumors

  • Chapter
Endoscopic Oncology

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors characterized by a spindle morphology and expression of the c-kit proto-oncogene. They occur primarily in the stomach and small intestine presenting with abdominal pain or bleeding, but may be found incidentally. These tumors may behave malignantly by metastasizing, invading adjacent organs, or recurring after resection. Tumor size more than 5 cm or more than 5 mitoses per high-power field (HPF) are most useful inpredicting subsequent malignant behavior. Endoscopy generally reveals a submucosal tumor that may have a central umbilication or ulcer. Endoscopic forceps biopsies are usually nondiagnostic. Endoscopic ultrasound (EUS) reveals a hypoechoic mass generally arising from the fourth endosonographic layer (muscularis propria). EUS-guided fine-needle aspiration (FNA) with staining of the specimen for the c-kit protein (CD-117) and CD-34 can establish the diagnosis. The treatment of choice is complete surgical resection for all tumors that have malignant features. Controversy surrounds whether small benign-appearing GISTs require resection. Patients with unresectable, metastatic and/or recurrent GISTs may be treated with the tyrosine kinase inhibitor imatinib mesylate with 80% of patients either responding or having stable disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc 2003; 58:80–88.

    Article  PubMed  Google Scholar 

  2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813–3825.

    Article  PubMed  CAS  Google Scholar 

  3. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459–465.

    Article  PubMed  Google Scholar 

  4. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100:162–168.

    Article  PubMed  Google Scholar 

  5. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998; 87:278–281.

    PubMed  CAS  Google Scholar 

  6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103:821–829.

    Article  PubMed  Google Scholar 

  7. Akwari OE, Dozois RR, Weiland LH, Beahrs OH. Leiomyosarcoma of the small and large bowel. Cancer 1978; 42:1375–1384.

    Article  PubMed  CAS  Google Scholar 

  8. Shiu MH, Farr GH, Papachristou DN, Hajdu SI. Myosarcomas of the stomach: Natural history, prognostic factors and management. Cancer 1982; 49:177–187.

    Article  PubMed  CAS  Google Scholar 

  9. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985; 56:2242–2250.

    Article  PubMed  CAS  Google Scholar 

  10. Horowitz J, Spellman JE, Driscoll DL, Velez AF, Karakousis CP. An institutional review of sarcomas of the large and small intestine. J Am Coll Surg 1995; 180:465–471.

    PubMed  CAS  Google Scholar 

  11. Miettinen M, Sarlomo-Rikala M, Sobin L, Lasota J. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24:211–222.

    Article  PubMed  CAS  Google Scholar 

  12. Hatch GF, Wertheimer-Hatch L, Hatch KF, et al. Tumors of the esophagus. World J Surg 2000; 24:401–411.

    Article  PubMed  Google Scholar 

  13. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52–68.

    Article  PubMed  Google Scholar 

  14. Blanchard DK, Budde JM, Hatch GF, et al. Tumors of the small intestine. World J Surg 2000; 24:421–429.

    Article  PubMed  CAS  Google Scholar 

  15. Goldblum JR, Appelman HD. Stromal tumors of the duodenum. A Histologic and immunohistochemical study of 20 cases. Am J Surg Pathol 1995; 19:71–80.

    PubMed  CAS  Google Scholar 

  16. Brainard JA, Goldblum JR. Stromal tumors of the jejunum and ileum. A clinopathologic study of 39 cases. Am J Surg Pathol 1997; 21:407–416.

    Article  PubMed  CAS  Google Scholar 

  17. Tworek JA, Appelman HD, Singleton TP, Greenson JK. Stromal tumors of the jejunum and ileum. Mod Pathol 1997; 10:200–209.

    PubMed  CAS  Google Scholar 

  18. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Onc 2001; 8:50–59.

    Article  CAS  Google Scholar 

  19. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24:1339–1352.

    Article  PubMed  CAS  Google Scholar 

  20. Hatch KF, Blanchard DK, Hatch GF, et al. Tumors of the appendix and colon. World J Surg 2000; 24:430–436.

    Article  PubMed  CAS  Google Scholar 

  21. Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix. A clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2001; 25:1433–1437.

    Article  PubMed  CAS  Google Scholar 

  22. Ortiz-Hidalgo C, de Leon Bojorge B, Albores-Saavedra J. Stromal tumor of the gallbladder with phenotype of interstitial cells of Cajal. A previously unrecognized neoplasm. Am J Surg Pathol 2000; 24:1420–1423.

    Article  PubMed  CAS  Google Scholar 

  23. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: A sensitive marker for gastrointestinal stromal tumors thatis more specific than CD34. Mod Pathol 1998; 11:728–734.

    PubMed  CAS  Google Scholar 

  24. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (kit). Mod Pathol 2000;13:1134–1142.

    Article  PubMed  CAS  Google Scholar 

  25. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1–12.

    Article  PubMed  CAS  Google Scholar 

  26. Miettinen M, Virolainen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors-Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19:207–216.

    PubMed  CAS  Google Scholar 

  27. Vliagoftis H, Worobec AS, Metcalfe DD. The protooncogene c-kit and c-kit ligand in human disease. J Allerg Clin Immunol 1997; 100:435–440.

    Article  CAS  Google Scholar 

  28. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63:167–174.

    Article  PubMed  CAS  Google Scholar 

  29. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma, and seminoma/dysgerminoma in human: Immunohistochemical study of formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994; 424:135–141.

    Article  PubMed  CAS  Google Scholar 

  30. Sanders KM. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology 1996; 111:492–515.

    Article  PubMed  CAS  Google Scholar 

  31. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal. Am J Pathol; 1999; 154:23–28.

    PubMed  CAS  Google Scholar 

  32. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259–1269.

    PubMed  CAS  Google Scholar 

  33. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577–580.

    Article  PubMed  CAS  Google Scholar 

  34. Nakahara M, Isozaki K, Hirota S, et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998; 115:1090–1095.

    Article  PubMed  CAS  Google Scholar 

  35. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001; 193:505–510.

    Article  PubMed  CAS  Google Scholar 

  36. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal tumor. J Clin Oncol 2003; 21:4342–4349.

    Article  PubMed  CAS  Google Scholar 

  37. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 1998; 19:323, 324.

    Article  PubMed  CAS  Google Scholar 

  38. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of the KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000; 157:1581–1585.

    PubMed  CAS  Google Scholar 

  39. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene. Gastroenterology 2001; 120:210–215.

    Article  PubMed  CAS  Google Scholar 

  40. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708–710.

    Article  PubMed  CAS  Google Scholar 

  41. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor ? gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660–667.

    Article  PubMed  CAS  Google Scholar 

  42. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357–5364.

    Article  PubMed  CAS  Google Scholar 

  43. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: Recent advances in understanding of their biology. Hum Pathol 1999; 30:1213–1220.

    Article  PubMed  CAS  Google Scholar 

  44. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MR. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51–58.

    Article  PubMed  CAS  Google Scholar 

  45. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103:41–47.

    PubMed  CAS  Google Scholar 

  46. Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 2002; 33:478–483.

    Article  PubMed  CAS  Google Scholar 

  47. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MR. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51–58.

    Article  PubMed  CAS  Google Scholar 

  48. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum. A pathologic analysis of 100 cases. Cancer 1977; 39:255–262.

    Article  PubMed  CAS  Google Scholar 

  49. Trupiano JK, Stewart RE, Misick C, Appelman HD, Goldblum JR. Gastric stromal tumors. A clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol 2002; 26:705–714.

    Article  PubMed  Google Scholar 

  50. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J of Surg Pathol 1999; 23:82–87.

    Article  CAS  Google Scholar 

  51. Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M. A clinico-pathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69:947–955.

    Article  PubMed  CAS  Google Scholar 

  52. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999; 154:53–60.

    PubMed  CAS  Google Scholar 

  53. Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999; 18:1897–1902.

    Article  PubMed  CAS  Google Scholar 

  54. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, O’Leary TJ. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998; 78:1633–1636.

    PubMed  CAS  Google Scholar 

  55. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118–8121.

    PubMed  CAS  Google Scholar 

  56. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297–4300.

    PubMed  CAS  Google Scholar 

  57. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567–1572.

    PubMed  CAS  Google Scholar 

  58. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000; 157:1091–1095.

    PubMed  CAS  Google Scholar 

  59. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001; 92:494–498.

    PubMed  CAS  Google Scholar 

  60. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res 2000; 60:3899–3903.

    PubMed  CAS  Google Scholar 

  61. O’Leary T, Ernst S, Przygodzki R, Emory T, Sobin L. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1999; 79:1461–1467.

    PubMed  CAS  Google Scholar 

  62. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach. A clinopathologic, Immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52–68.

    Article  PubMed  Google Scholar 

  63. Savides TJ. Gastrointestinal submucosal masses. In: Gress FG, Battacharya I, eds. Endoscopic Ultrasonography. Malden: Blackwell Science; 2001:92–102.

    Google Scholar 

  64. Chak A, Canto MI, Rosch T, et al. Endosonographic differentiation of benign and malignant gastrointestinal stromal cell tumors. Gastrointest Endosc 1997; 45:468–473.

    Article  PubMed  CAS  Google Scholar 

  65. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP. Endosonographic features predictive of benign and malignant gastrointestinal stromal cell tumours. Gut 2000; 46:88–92.

    Article  PubMed  CAS  Google Scholar 

  66. Gu M, Ghafari S, Nguyen PT, Lin F. Cytologic diagnosis of gastrointestinal stromal tumors of the stomach by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cytomorphologic and immunohistochemical study of 12 cases. Diagn Cytopathol 2001; 25:343–350.

    Article  PubMed  CAS  Google Scholar 

  67. Rader AE, Avery A, Wait CL, McGreevey LS, Faigel D, Heinrich MC. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer Cytopathol 2001; 93: 269–275.

    CAS  Google Scholar 

  68. Ando N, Goto H, Niwa Y, et al. The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 2002; 55:37–43.

    Article  PubMed  Google Scholar 

  69. Hunt GC, Rader AE, Faigel DO. A comparison of EUS features between CD-1 17 positive GI stromal tumors and CD-1 17 negative GI spindle cell tumors. Gastrointest Endosc 2003; 57(4):69–74.

    Article  Google Scholar 

  70. Lehnert T. Gastrointestinal sarcoma (GIST)—A review of surgical management. Ann Chir Gynaecol 1998; 87:297–305.

    PubMed  CAS  Google Scholar 

  71. Ng E-H, Pollock, RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic Factors influencing survival in gastrointestinal leiomyosar-comas: Implications for surgical management and staging. Ann Surg 1992; 215:68–77.

    Article  PubMed  CAS  Google Scholar 

  72. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott, MJ. The effect of surgery and grade on outcome of Gastrointestinal Stromal tumors. Arch Surg 2001; 136:383–389.

    Article  PubMed  CAS  Google Scholar 

  73. Von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematol Onc Clin N Am 2005; 19:547–564.

    Article  Google Scholar 

  74. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88:66–74.

    Article  PubMed  CAS  Google Scholar 

  75. DeMatteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234:540–548.

    Article  PubMed  CAS  Google Scholar 

  76. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925–932.

    PubMed  CAS  Google Scholar 

  77. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054–5058.

    Article  PubMed  CAS  Google Scholar 

  78. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421–1423.

    Article  PubMed  Google Scholar 

  79. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472–480.

    Article  PubMed  CAS  Google Scholar 

  80. Verweij J, van Oosterom A, Blay J-Y, et al. Imatinib mesylate (STI-571 Glivec®, Geevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase n study. Eur J Cancer 2003; 39:2006–2011.

    Article  PubMed  CAS  Google Scholar 

  81. Rankin C, von Mehren M, Blanke C, et al. Dose effect of imatinim (IM) in patients (pts) with metastatic GIST—Phase III Sarcoma Group Study S0033. Proc Annu Meet Am Soc Clin Oncol 2004. Abstract 9005.

    Google Scholar 

  82. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial. Lancet 2004; 364:1127–1134.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Oregon Health and Science University, Portland, OR

    Raquel E. Davila MD

Authors
  1. Raquel E. Davila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Portland, OR

    Douglas O. Faigel MD, FACG, FASGE (Associate Professor of Medicine, Director of Endoscopy) (Associate Professor of Medicine, Director of Endoscopy)

  2. Hospital of the University of Pennsylvania, Philadelphia, PA

    Michael L. Kochman MD, FACP, FASGE (Professor of Medicine and Surgery, Co-Director Gastrointestinal Oncology) (Professor of Medicine and Surgery, Co-Director Gastrointestinal Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Davila, R.E. (2006). Gastrointestinal Stromal Tumors. In: Faigel, D.O., Kochman, M.L. (eds) Endoscopic Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-172-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-172-7_14

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-532-3

  • Online ISBN: 978-1-59745-172-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation